Rabbit anti-PTRF Antibody Affinity Purified

Product Details
Specifications
The epitope recognized by A301-271A maps to a region between residue 238 and 288 human RNA polymerase I and transcript release factor using the numbering given in entry NP_036364.2 (GeneID 284119).
Immunoglobulin concentration was determined using Beer’s Law where 1mg/mL IgG has an A280 of 1.4. Antibody was affinity purified using an epitope specific to PTRF immobilized on solid support.
The epitope recognized by A301-271A-T maps to a region between residue 238 and 288 human RNA polymerase I and transcript release factor using the numbering given in entry NP_036364.2 (GeneID 284119).
Additional Product Information
PTRF (polymerase I and transcript release factor) was first identified as a TTF-I and RNA polymerase I (RNA Pol I) interacting protein that functions in the termination of RNA polymerase I transcription. PTRF has also been described as a protein that localizes to the plasma membrane and caveolae of adipocytes and whose localization is under the control of insulin. In this context, PTRF has been observed to associate with a lipase and have an extranuclear role in the regulation of lipolysis.
Alternate Names
caveolae-associated protein 1; CAVIN; cavin-1; CGL4; congenital generalized lipodystrophy 4; FKSG13; polymerase I and transcript release factor; PTRF; RNA polymerase I and transcript release factor; TTF-I interacting peptide 12
Applications
All western blot analysis is performed using 5% Milk-TBST for blocking and as antibody diluent. Primary antibody is incubated overnight.
Western blots of cell lysates are performed using Goat anti-Rabbit IgG Heavy and Light Chain Antibody (Cat. No. A120-101P).
Western blots of immunoprecipitates are performed using Goat anti-Rabbit Light Chain HRP Conjugate (Cat. No. A120-113P) with 5% Normal Pig Serum (Cat. No. S100-020) added to the blocking buffer.